Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
- PMID: 10102478
Item in Clipboard
Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Thromb Haemost.
1999 Mar.
No abstract available
Similar articles
-
Registry of DNA polymorphisms within or close to the human factor VIII and factor IX genes. For the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.Thromb Haemost. 1992 Feb 3;67(2):277-80. Thromb Haemost. 1992. PMID: 1352417 No abstract available.
-
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.Thromb Haemost. 2001 Mar;85(3):560. Thromb Haemost. 2001. PMID: 11307831 No abstract available.
-
The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.Thromb Haemost. 1991 Sep 2;66(3):384-6. Thromb Haemost. 1991. PMID: 1746011 No abstract available.
-
In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.Thromb Haemost. 1995 Oct;74(4):1191-6. Thromb Haemost. 1995. PMID: 8560434 Review.
-
Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.Haemophilia. 2006 Dec;12 Suppl 6:37-41; discussion 41-2. doi: 10.1111/j.1365-2516.2006.01364.x. Haemophilia. 2006. PMID: 17123392 Review.
Cited by
-
Inhibitors in previously treated patients: a review of the literature.Haemophilia. 2010 May;16(102):61-5. doi: 10.1111/j.1365-2516.2010.02235.x. Haemophilia. 2010. PMID: 20536987 Free PMC article. Review.
-
Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.Int J Hematol. 2009 Nov;90(4):446-454. doi: 10.1007/s12185-009-0435-x. Epub 2009 Nov 3. Int J Hematol. 2009. PMID: 19882376 Review.
-
Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.Clin Rev Allergy Immunol. 2009 Oct;37(2):125-34. doi: 10.1007/s12016-009-8115-4. Clin Rev Allergy Immunol. 2009. PMID: 19184560 Review.
-
Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.Clin Rev Allergy Immunol. 2009 Oct;37(2):114-24. doi: 10.1007/s12016-009-8122-5. Clin Rev Allergy Immunol. 2009. PMID: 19199081 Review.
-
Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A.Thromb Res. 2014 Nov;134 Suppl 1:S38-42. doi: 10.1016/j.thromres.2013.10.015. Epub 2013 Nov 17. Thromb Res. 2014. PMID: 24256767 Free PMC article.